Deutsche Märkte geschlossen

Adaptive Biotechnologies Corporation (1HM.F)

Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
2,9900+0,3590 (+13,65%)
Börsenschluss: 04:38PM CET

Adaptive Biotechnologies Corporation

1165 Eastlake Avenue East
Seattle, WA 98109
United States
206 659 0067
https://www.adaptivebiotech.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter709

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Chad M. Robins M.B.A.Co-Founder, CEO & Chairman1,09M229,64k1974
Ms. Julie RubinsteinPresident & COO702,07kN/A1972
Dr. Harlan S. Robins Ph.D.Co-Founder & Chief Scientific Officer701,27kN/A1973
Mr. Tycho W. PetersonChief Financial Officer498,28kN/A1974
Mr. Kyle PiskelVP & Principal Accounting Officer347,04kN/A1984
Dr. Sharon Benzeno Ph.D.Chief Commercial Officer of Immune Medicine619,74kN/A1974
Mr. Christopher Carlson Ph.D.FounderN/AN/AN/A
Karina CalzadillaVice President of Investor RelationsN/AN/AN/A
Ms. Stacy L. TaylorSenior VP, General Counsel & Corporate SecretaryN/AN/A1960
Mr. Francis T. LoChief People OfficerN/AN/A1981
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Corporate Governance

Adaptive Biotechnologies Corporations ISS Governance QualityScore, Stand 1. März 2024, lautet 8. Die grundlegenden Scores sind Audit: 6, Vorstand: 8, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.